Dear Madam/ Sir,

It is pleasure to invite you to attend


17 January 2020 (Friday), 10:00 – 16:00 EET
European Commission Representation in Bulgaria
124 Georgi S. Rakovski Str., Sofia, Bulgaria

The upcoming IMI2 information day aims to bring together representatives and key figures from research and business area in Bulgaria and SEE in order to boost application and participation of CE and SEE countries in different IMI calls and projects. The first of two planned events will be held on 17th of January 2020 in Sofia.

Along with the general information about IMI, a representative from the initiative will join the workshop and will present detailed information about the upcoming funding opportunities in 2020, as the focus will be on IMI2 – Call 20.

Participants will have the unique opportunity to exchange information and to share ideas, experience and good practices from the field, searching for the answer of the question “How could Bulgaria be successful in the upcoming IMI calls?”.
The event is organized by Bulgarian Association for Personalized Medicine and Biotech Atelier.
The access is freе!


Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI does this by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). Through the IMI2 programme, the Initiative has a €3.3 billion budget for the period 2014-2020.

The goal of IMI, particularly in its second phase (IMI2, 2014-2020) is to develop next generation vaccines, medicines and treatments, such as new antibiotics. IMI2 projects will provide Europeans, including the increasing numbers of older people, with more efficient and effective medicines and treatments. Greater coordination across industry sectors will result in more reliable and faster clinical trials, and better regulation. IMI research and innovation efforts will also open new commercial possibilities based on new services and products. The research, industry and societal sectors involved in IMI2 will benefit from the cooperation and knowledge sharing which take place in these projects.